Sandostatin is a synthetic hormone injection used to treat three main conditions: acromegaly (excess growth hormone), carcinoid tumors, and VIPomas. The drug mimics a natural hormone called somatostatin, which acts as a brake on several hormones and chemical messengers in your body. By slowing down hormone release, Sandostatin helps control the uncomfortable and sometimes dangerous symptoms these conditions cause.
How Sandostatin Works
Your body naturally produces somatostatin, a hormone that tells other glands to slow down or stop releasing their own hormones. Sandostatin (generic name: octreotide) is a lab-made version of somatostatin that’s actually more powerful than the natural form. It suppresses growth hormone, insulin, glucagon, and a range of gut-related chemical signals including serotonin, gastrin, and vasoactive intestinal peptide. It also reduces blood flow to the digestive organs, which matters in certain emergency situations.
This broad ability to dial down hormone output is what makes Sandostatin useful across several very different conditions. In each case, the underlying problem is a hormone or signaling molecule being produced in excess, and Sandostatin steps in to reduce that overproduction.
Acromegaly
Acromegaly happens when a benign tumor on the pituitary gland pumps out too much growth hormone. Over time, this leads to enlarged hands, feet, and facial features, along with joint pain, diabetes, and heart problems. Sandostatin is prescribed when surgery or radiation hasn’t fully controlled the disease, or when those treatments aren’t an option.
The treatment goals are specific: bring a key marker called IGF-1 (a downstream signal of growth hormone) into the normal range for the person’s age and sex, and lower growth hormone itself to very low levels. Achieving these targets helps reverse metabolic problems like elevated blood sugar, reduces ongoing tissue growth, and can shrink the pituitary tumor in some patients. Many people on Sandostatin for acromegaly stay on it long term, since the condition is chronic.
Carcinoid Tumors
Carcinoid tumors are slow-growing tumors, often found in the digestive tract or lungs, that release excess serotonin and other substances into the bloodstream. When these tumors spread (metastasize), they can trigger what’s known as carcinoid syndrome: severe flushing of the skin and frequent, watery diarrhea that can be debilitating.
Sandostatin doesn’t cure the tumors, but it suppresses or inhibits the flushing and diarrhea by blocking the release of serotonin and other active substances from the tumor cells. For many patients, this makes a dramatic difference in daily quality of life, turning unmanageable symptoms into something controllable.
VIPomas
VIPomas are rare tumors, usually in the pancreas, that secrete large amounts of vasoactive intestinal peptide (VIP). The hallmark symptom is profuse, watery diarrhea, sometimes several liters per day, which leads to dangerous dehydration and electrolyte imbalances. This combination is sometimes called “pancreatic cholera.”
Sandostatin directly blocks VIP release, reducing the volume of diarrhea and giving the body a chance to recover fluid and electrolyte balance. Treatment typically also includes aggressive hydration and electrolyte replacement, and surgery may be needed to remove or reduce the tumor itself.
Off-Label Uses
Doctors also use Sandostatin for conditions beyond its three approved indications. One of the most common is acute bleeding from esophageal varices, the swollen veins in the esophagus that can rupture in people with liver cirrhosis. In a randomized trial comparing octreotide to an older drug (vasopressin), octreotide initially controlled bleeding in 88% of patients within six hours, compared to 54% with vasopressin, and caused significantly fewer side effects like headache and chest pain. It’s typically used as a bridge to buy time until a procedure can seal the bleeding veins.
Other off-label uses include managing dumping syndrome after stomach surgery (where food moves too quickly into the small intestine, causing nausea and diarrhea) and controlling certain types of severe, treatment-resistant diarrhea.
How It’s Given
Sandostatin comes in two forms. The standard version is a subcutaneous injection (just under the skin) given two to four times per day. Its effects last up to 12 hours depending on the condition being treated, which is why multiple daily doses are needed.
For long-term use, there’s Sandostatin LAR, a slow-release formulation injected into the gluteal muscle once every four weeks. The medication is embedded in tiny biodegradable microspheres that dissolve gradually, releasing a steady supply of the drug over the month. LAR injections cannot be given intravenously, under the skin, or into the deltoid (shoulder) muscle. Patients often start on the daily injection to see how they respond before switching to the monthly version.
Side Effects and Gallbladder Risk
The most notable long-term risk with Sandostatin is its effect on the gallbladder. In clinical trials, 63% of patients developed some type of biliary tract abnormality: 27% developed gallstones, 24% had sludge buildup without stones, and 12% had bile duct widening. Among patients treated for 12 months or longer, 52% developed stones or sludge. By contrast, fewer than 2% of people treated for a month or less had any gallstone formation. This is why patients on long-term therapy are typically monitored with periodic ultrasounds.
Because Sandostatin suppresses both insulin and glucagon, it can shift blood sugar levels in either direction. People with diabetes may need their medications adjusted when starting or changing the dose. Other common side effects include nausea, abdominal discomfort, and loose stools, particularly when treatment first begins.
Important Drug Interactions
Sandostatin can lower blood levels of cyclosporine, an anti-rejection drug used after organ transplants, potentially leading to transplant rejection if not caught. It increases the effects of bromocriptine, a medication sometimes used alongside it for acromegaly. When combined with beta-blockers or other drugs that slow heart rate, the heart rate reduction can become excessive.
One interaction worth knowing about: if you’re receiving a targeted cancer treatment called lutetium Lu 177 dotatate (used for certain neuroendocrine tumors), Sandostatin must be stopped at least 24 hours before each dose. Both drugs compete for the same receptors on tumor cells, so Sandostatin can block the cancer therapy from reaching its target. The only true contraindication to Sandostatin is an allergy to the drug or any of its ingredients.